|
Aug 5
|
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
|
|
Aug 5
|
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
|
|
Jun 11
|
Sidoti Events, LLC's Virtual June Small-Cap Conference
|
|
May 21
|
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
|
|
May 14
|
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
|
|
May 10
|
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
|
|
Apr 30
|
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
|
|
Apr 26
|
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
|
|
Apr 11
|
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
|
|
Apr 4
|
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
|
|
Mar 18
|
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
|
Mar 12
|
Sidoti Events, LLC's Virtual March Small-Cap Conference
|
|
Mar 7
|
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
|
|
Dec 3
|
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
|